Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma Journal Article


Authors: Miao, D.; Margolis, C. A.; Gao, W.; Voss, M. H.; Li, W.; Martini, D. J.; Norton, C.; Bossé, D.; Wankowicz, S. M.; Cullen, D.; Horak, C.; Wind-Rotolo, M.; Tracy, A.; Giannakis, M.; Hodi, F. S.; Drake, C. G.; Ball, M. W.; Allaf, M. E.; Snyder, A.; Hellmann, M. D.; Ho, T.; Motzer, R. J.; Signoretti, S.; Kaelin, W. G. Jr; Choueiri, T. K.; Van Allen, E. M.
Article Title: Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Abstract: Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To identify genomic alterations in ccRCC that correlate with response to anti–PD-1 monotherapy, we performed whole-exome sequencing of metastatic ccRCC from 35 patients. We found that clinical benefit was associated with loss-of-function mutations in the PBRM1 gene (P = 0.012), which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex. We confirmed this finding in an independent validation cohort of 63 ccRCC patients treated with PD-1 or PD-L1 (PD-1 ligand) blockade therapy alone or in combination with anti–CTLA-4 (cytotoxic T lymphocyte-associated protein 4) therapies (P = 0.0071). Gene-expression analysis of PBAF-deficient ccRCC cell lines and PBRM1-deficient tumors revealed altered transcriptional output in JAK-STAT (Janus kinase–signal transducers and activators of transcription), hypoxia, and immune signaling pathways. PBRM1 loss in ccRCC May alter global tumor-cell expression profiles to influence responsiveness to immune checkpoint therapy. © 2018 American Association for the Advancement of Science. All Rights Reserved.
Journal Title: Science
Volume: 359
Issue: 6377
ISSN: 0036-8075
Publisher: American Association for the Advancement of Science  
Date Published: 2018-02-16
Start Page: 801
End Page: 806
Language: English
DOI: 10.1126/science.aan5951
PROVIDER: scopus
PUBMED: 29301960
PMCID: PMC6035749
DOI/URL:
Notes: Article -- Export Date: 1 March 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer
  2. Martin Henner Voss
    288 Voss
  3. Matthew David Hellmann
    412 Hellmann